Business Model Breakdown
How Axsome Therapeutics Inc Makes Money
AXSM
Market Cap
$9.4B
Annual Revenue
$561M
Profit Margin
-40.9%
Employees
816
The Short Version
Axsome Therapeutics is a pharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders. They primarily generate revenue by selling their approved drugs, such as Auvelity for major depressive disorder and Sunosi for narcolepsy/excessive daytime sleepiness, to patients through pharmacies. Their business model involves extensive research and development to discover new treatments, navigating rigorous regulatory approval processes to gain market access, and then building commercial infrastructure, including a large sales force, to market and distribute their products. Success hinges on drug efficacy, market adoption, and robust intellectual property protection.
Where the Revenue Comes From
Auvelity sales for Major Depressive Disorder (~79% of Q4 2025 revenue)
Sunosi sales for narcolepsy/EDS (~21% of Q4 2025 revenue, based on deduction)
Who buys: Prescribing physicians, pharmacies, and ultimately patients suffering from CNS disorders.
Why It Works (Competitive Advantages)
- ✔Differentiated mechanism of action for Auvelity (NMDA receptor antagonist)
- ✔Strong gross margins (93%) on current products
- ✔Experienced commercial and regulatory team in CNS disorders
Economic Moat: Narrow (Intangible Assets/IP (patent protection on Auvelity, AXS-05))
What Our Analysis Says
DVR Score as of April 9, 2026
Axsome Therapeutics maintains its strong trajectory, slightly improving its score due to the increased proximity of the pivotal AXS-05 (Auvelity for Alzheimer's agitation) PDUFA date on April 30, 2026, which substantially de-risks a major growth catalyst. Robust commercial execution for Auvelity (68% YoY growth) and Sunosi (40% YoY growth) continues to drive revenue (66% YoY overall). While profitability remains a challenge with a net loss, the 93% gross margin and significant cash position ($323M vs $190M debt) provide stability. The strategic expansion of the sales force for a broader market penetration post-approval, coupled with positive analyst sentiment, underscores a compelling case for substantial long-term appreciation within the 3-5 year timeframe, despite inherent biotech regulatory and commercialization risks.